fr   en

Browse by date
Or search by keyword
Date: 2010-06-17
Company: Ipsogen (France)
Investors: historical shareholders and new investors
Amount: € 1.9 million
Planned use: This capital increase reinforces Ipsogen’s financial structure with a very limited dilution effect. Ipsogen already markets more than 80 molecular diagnostic tests for the diagnosis, prognosis and follow-up of of patients with leukemia. The company is now also targeting breast cancer and is striving to become the leader in the molecular profiling of cancers.
Other: Ipsogen has successfully completed a €1.9 million capital increase reserved for qualified investors. Through this capital increase, which was managed by Portzamparc, a total of 211 200 shares were issued at a price of €9.20 each.
Pursuant to the delegation of the Company’s Annual General Meeting held on May 20, 2009, this
fundraising has been implemented in the context of the French « TEPA » law which allows a reduction of the French Wealth Tax in favor of investments in SMEs.